AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...

Eli Lilly (LLY) closed the latest trading day at $822.27, indicating a -0.22% change from the previous session's end. This change lagged the S&P 500's daily gain of 0.49%. Elsewhere, the Dow lost 0.2% ...

Novo Nordisk’s NVO stock declined 4.3% on Wednesday after Roche RHHBY announced a license and collaboration deal worth $5.3 ...

Dow, S&P 500, and Nasdaq futures are falling in premarket trading Thursday as the stock market digests CPI inflation data and braces for Trump's response to Canada and EU tariffs.

Axiomer ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Company expect ...

Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., February 12, 2025. REUTERS/Brendan McDermid/File photo ...

Eli Lilly (LLY) stock dropped by 0.22%, underperforming the S&P 500’s 0.49% gain. Over the past month, the stock has fallen 4 ...